S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Travere Therapeutics Stock Forecast, Price & News

-1.40 (-4.81 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $27.72
50-Day Range
MA: $26.10
52-Week Range
Now: $27.72
Volume267,896 shs
Average Volume412,277 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Travere Therapeutics logo


Overall MarketRank

0.86 out of 5 stars

Medical Sector

887th out of 1,480 stocks

Pharmaceutical Preparations Industry

423rd out of 612 stocks

Analyst Opinion: 1.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RTRX
Phone(888) 969-7879



Sales & Book Value

Annual Sales$175.34 million
Book Value$5.15 per share


Net Income$-146,430,000.00


Market Cap$1.42 billion
Next Earnings Date2/22/2021 (Estimated)
-1.40 (-4.81 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Travere Therapeutics (NASDAQ:RTRX) Frequently Asked Questions

How has Travere Therapeutics' stock price been impacted by Coronavirus?

Travere Therapeutics' stock was trading at $14.79 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RTRX shares have increased by 87.4% and is now trading at $27.72.
View which stocks have been most impacted by COVID-19

Is Travere Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Travere Therapeutics stock.
View analyst ratings for Travere Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Travere Therapeutics?

Wall Street analysts have given Travere Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Travere Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Travere Therapeutics' next earnings date?

Travere Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Travere Therapeutics

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:RTRX) released its quarterly earnings data on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative return on equity of 36.38% and a negative net margin of 49.13%.
View Travere Therapeutics' earnings history

What price target have analysts set for RTRX?

6 brokers have issued 12 month price targets for Travere Therapeutics' shares. Their forecasts range from $21.00 to $33.00. On average, they anticipate Travere Therapeutics' stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 1.0% from the stock's current price.
View analysts' price targets for Travere Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Travere Therapeutics' key competitors?

What other stocks do shareholders of Travere Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Travere Therapeutics investors own include CVS Health (CVS), Gilead Sciences (GILD), TG Therapeutics (TGTX), Dynavax Technologies (DVAX), Novavax (NVAX), Sangamo Therapeutics (SGMO), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK) and Exelixis (EXEL).

Who are Travere Therapeutics' key executives?

Travere Therapeutics' management team includes the following people:
  • Eric Dube, President, Chief Executive Officer & Director
  • Laura M. Clague, Chief Financial & Accounting Officer
  • Bill Rote, Senior VP, Head-Research & Development
  • Noah L. Rosenberg, Chief Medical Officer
  • Elizabeth E. Reed, Secretary, Senior Vice President & General Counsel

What is Travere Therapeutics' stock symbol?

Travere Therapeutics trades on the NASDAQ under the ticker symbol "RTRX."

How do I buy shares of Travere Therapeutics?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Travere Therapeutics' stock price today?

One share of RTRX stock can currently be purchased for approximately $27.72.

How big of a company is Travere Therapeutics?

Travere Therapeutics has a market capitalization of $1.42 billion and generates $175.34 million in revenue each year. The biopharmaceutical company earns $-146,430,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. Travere Therapeutics employs 221 workers across the globe.

What is Travere Therapeutics' official website?

The official website for Travere Therapeutics is www.retrophin.com.

How can I contact Travere Therapeutics?

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at (888) 969-7879 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.